One of the most important peptide updates of 2026 has arrived from an unexpected direction.
Rather than a new study or a clinical trial result, the shift has come from a regulatory announcement.
Secretary Robert F. Kennedy Jr. confirmed that 12 peptides previously restricted under FDA Category 2 will be removed from that classification and referred to the Pharmacy Compounding Advisory Committee (PCAC) for independent, evidence-based evaluation.
The compounds affected include some of the most widely researched peptides in the field, among them BPC-157, Epitalon, and Semax.
For the research and clinical community that has worked with these compounds for years, this 2026 peptide update represents a meaningful step towards science-led decision making.
The FDA’s bulk drug substance nomination process determines which compounds compounding pharmacies may legally use to prepare medications for individual patients under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Substances are reviewed and assigned to categories based on their clinical, pharmacological, and safety profiles.
Category 2 designates compounds considered to raise significant safety risks under this framework.
Placement in Category 2 removes a substance from the regulated compounding pathway, preventing compounding pharmacies from legally preparing it for patients.
In September 2023, the Biden-era FDA assigned a number of well-researched peptides to Category 2.
Secretary Kennedy’s 2026 announcement directly addressed the consequences of that decision, describing it as having created a dangerous black market by pushing demand away from regulated, quality-controlled compounding pharmacies and toward unregulated sources.
The 2026 peptide update is the regulatory response to that outcome.
The following 12 compounds will be removed from Category 2 and brought before the PCAC for independent scientific evaluation:
The Pharmacy Compounding Advisory Committee (PCAC) is an independent body that advises the FDA on matters related to pharmaceutical compounding.
Its specific function in this context is to evaluate substances nominated for inclusion on the Section 503A Bulk Drug Substances List, which governs what compounding pharmacies may legally prepare for individual patients.
The upcoming PCAC meetings are scheduled for 23 and 24 July 2026 at the FDA White Oak Campus in Silver Spring, Maryland.
Both sessions will be accessible to the public via online teleconferencing. A public docket (Docket No. FDA-2025-N-6895) has been opened for comments ahead of the meetings.
At these sessions, independent experts will assess each of the 12 peptides using the full body of available clinical, pharmacological, and safety evidence.
The PCAC provides recommendations to the FDA, which retains final decision-making authority.
A favourable PCAC recommendation substantially improves the prospect of a compound being added to the 503A list, restoring the ability of regulated compounding pharmacies to prepare it for patients.
The PCAC review is an evidence-driven process. For compounds with robust, peer-reviewed research profiles, the July 2026 meetings represent the appropriate forum for that science to be formally evaluated.
Several of the 12 peptides in this 2026 peptide update bring particularly compelling evidence to the table.
The preclinical literature on BPC-157 is among the most extensive in the peptide research space.
Over 100 peer-reviewed publications, the majority from Professor Predrag Sikiric’s group at the University of Zagreb, document its cytoprotective, anti-inflammatory, and tissue repair properties across the gastrointestinal tract, musculoskeletal system, nervous system, and cardiovascular tissue.
A review by Sikiric et al. (2020), described BPC-157 as a novel cytoprotective mediator with organ-protective effects extending well beyond its original gastrointestinal research context.
The breadth and consistency of this evidence base makes it one of the strongest cases entering the PCAC process.
The research profile behind Epitalon spans several decades of work by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. A peer-reviewed study (Khavinson et al., 2003) confirmed that Epitalon induces telomerase activity and promotes telomere elongation in human somatic cells, establishing a clear mechanistic basis for its classification as a longevity-focused research peptide.
Research has also documented Epitalon‘s influence on sleep regulation through pineal gland modulation, immune function, and metabolic balance, giving it one of the most multifaceted evidence profiles among the 12 peptides in this update.
Among the 12 peptides in this 2026 peptide update, Semax stands out for having an established prescription history.
Approved in Russia since the late 1990s for stroke treatment and cognitive support, Semax brings real-world clinical use data to the PCAC review alongside its preclinical research profile.
Research by Dolotov et al. (2006), confirmed that Semax upregulates BDNF protein levels and trkB receptor expression in the rat hippocampus following intranasal application.
This provides a well-characterised neurobiological basis for its nootropic and neuroprotective properties that the PCAC process will be able to evaluate directly.
Interpreting the 2026 peptide update accurately is as important as understanding what happened. Several things are simultaneously true.
The 2026 peptide update brings renewed attention to 12 of the most researched compounds in the field.
Understanding which of them are relevant to your specific health goals, how they work, and how to use them safely requires more than reading a regulatory announcement. It requires expert guidance tailored to your individual biology and protocol.
The UAE Peptide Research team offers 1:1 tailored consultations with our Peptide Therapy expert who can help you navigate the science, identify the peptides most relevant to your goals, and design a protocol grounded in the evidence. Book a call today.
Schedule your consultation today
FDA Category 2 designates bulk drug substances considered to raise significant safety risks under the compounding framework. Placement in Category 2 prevented regulated compounding pharmacies from legally preparing these substances for individual patients under Section 503A, effectively removing them from quality-controlled compounding channels.
Removal from Category 2 means each of the 12 peptides is no longer designated as raising significant safety risks under the compounding framework. The compounds will now be evaluated by the PCAC using full scientific evidence. Removal alone does not restore compounding access. That determination follows the PCAC review process and the FDA’s subsequent decision.
The PCAC meetings are scheduled for 23 and 24 July 2026 at the FDA White Oak Campus in Silver Spring, Maryland, with an online participation option available. A public docket (Docket No. FDA-2025-N-6895) has been established for written comments ahead of the meetings.
This 2026 peptide update is specific to the US pharmaceutical compounding regulatory framework. Researchers and practitioners in other regions should refer to applicable local regulations. That said, the FDA’s decisions carry significant influence internationally, and the outcomes of the PCAC review may shape the broader global evidence conversation around these compounds.
BPC-157, Epitalon, and Semax each bring extensive and well-documented research profiles to the PCAC process. BPC-157 has over 100 peer-reviewed publications. Epitalon has several decades of telomere and longevity research. Semax has both peer-reviewed mechanistic data and an established prescription history in Russia, giving it a particularly strong combined evidence base.
Updates will be published through official FDA channels and the public docket. The UAE Peptide Research team will also continue to publish updates as the review process progresses.
Written by Elizabeth Sogeke, BSc Genetics, MPH
Elizabeth is a science and medical writer with a background in Genetics and Public Health. She holds a BSc in Genetics and a Master’s in Public Health (MPH), with a focus on mitochondrial science, metabolic health, and healthy aging. Over the past several years, she has worked with leading peptide research laboratories and functional medicine clinics, creating trusted, clinically-informed content that bridges the latest developments in peptide and longevity research with real-world applications.
Discount Applied Successfully!
Your savings have been added to the cart.
